Cell and Gene Therapy Market Opportunities and Strategies to 2030: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global cell and gene therapy market as it emerges from the COVID-19 shut down.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Description:
Where is the largest and fastest growing market for the cell and gene therapy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Cell and gene therapy market global report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider cell and gene therapy market, and compares it with other markets.
The report covers the following chapters:
- Executive Summary - The executive summary section of the report gives a brief overview and summary of the report
- Report Structure - This section gives the structure of the report and the information covered in the various sections.
- Introduction - The introduction section of the report gives brief introduction about segmentation by geography, segmentation by type and by interest rate.
- Market Characteristics - The market characteristics section of the report defines and explains the cell and gene therapy market. This chapter also defines and describes goods and related services covered in the report.
- Supply Chain - The supply chain section of the report defines and explains the key players in the cell and gene therapy industry supply chain.
- Product/Service Analysis - The product/service analysis section of the report describes the leading products/services in the cell and gene therapy market along with key features and differentiators for those products/services.
- Customer Information - This chapter covers recent customers’ trends/preferences in the global cell and gene therapy market.
- Trends and Strategies - This chapter describes the major trends shaping the global cell and gene therapy market. This section highlights likely future developments in the market and suggests approaches companies can take to exploit these opportunities.
- Impact of COVID-19 - This section describes the impact of COVID-19 on the cell and gene therapy market.
- Global Market Size and Growth - This section contains the global historic (2015-2019) and forecast (2019-2023), (2023-2025), and (2025-2030) market values, and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
- Regional Analysis - This section contains the historic (2015-2019) and forecast (2019-2023), (2023-2025), and (2025-2030) market values and growth and market share comparison by region.
- Segmentation - This section contains the market values (2015-2030) and analysis for different segments.
- Global Macro Comparison - The global cell and gene therapy market comparison with macro-economic factors gives the cell and gene therapy market size, percentage of GDP, and average cell and gene therapy market expenditure.
- Regional Market Size and Growth - This section contains the region’s market size (2019), historic (2015-2019) and forecast (2019-2023), (2023-2025), and (2025-2030) market values, and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region. The market overview sections of the report describe the current size of the market, background information, government initiatives, regulations, regulatory bodies, associations, corporate tax structure, investments, and major companies.
- Competitive Landscape - This section covers details on the competitive landscape of the global cell and gene therapy market, estimated market shares and company profiles for the leading players.
- Key Mergers and Acquisitions - This chapter gives the information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
- Market Background - This section describes the cell and gene therapy market. This chapter includes the global cell and gene therapy market 2015-19 and 2019-23 values, and regional analyses for the cell and gene therapy market.
- Market Opportunities and Strategies - This section includes market opportunities and strategies based on findings of the research. This section also gives information on growth opportunities across countries, segments and strategies to be followed in those markets. It gives an understanding of where there is significant business to be gained by competitors in the next five years.
- Conclusions and Recommendations - This section includes conclusions and recommendations based on findings of the research. This section also gives recommendations for cell and gene therapy companies in terms of product/service offerings, geographic expansion, marketing strategies and target groups.
- Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Scope
Markets Covered:
1) By Product: Cell Therapy; Gene Therapy
2) By Application: Oncology; Neurological Disorders; Others
Companies Mentioned: Biogen Inc.; Novartis AG; Gilead Sciences; Ionis Pharmaceuticals, Inc.; Alnylam Pharmaceuticals Inc.
Metrics Covered: Number of Enterprises; Number of Employees
Countries: USA; China; Japan; Germany; France; UK; Russia; India; Brazil; Australia; South Korea; Indonesia
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita, cell and gene therapy indicators comparison.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Table of Contents
1. Cell and Gene Therapy Market Executive Summary2. Table of Contents3. List of Figures4. List of Tables5. Report Structure
6. Introduction
7. Cell and Gene Therapy Market Characteristics
8. Cell and Gene Therapy Market Trends and Strategies
9. Impact Of COVID-19 On The Cell and Gene Therapy Market
10. Global Cell and Gene Therapy Market Size and Growth
11. Global Cell and Gene Therapy Market Segmentation
12. Cell and Gene Therapy Market, Regional and Country Analysis
13. Asia-Pacific Cell and Gene Therapy Market
14. Western Europe Cell and Gene Therapy Market
15. Eastern Europe Cell and Gene Therapy Market
16. North America Cell and Gene Therapy Market
17. South America Cell and Gene Therapy Market
18. Middle East Cell and Gene Therapy Market
19. Africa Cell and Gene Therapy Market
20. Global Cell and Gene Therapy Market Competitive Landscape
21. Key Mergers and Acquisitions In The Cell and Gene Therapy Market
22. Cell and Gene Therapy Market Opportunities and Strategies
23. Cell and Gene Therapy Market, Conclusions and Recommendations
24. Appendix
Executive Summary
This report describes and explains the global cell and gene therapy market and covers 2015 to 2020, termed the historic period, and 2020 to 2025 termed the forecast period, along with further forecasts for the period 2025-2030. The report evaluates the market across each region and for the major economies within each region.The global cell and gene therapy market reached a value of nearly $4,390.3 million in 2020, having increased at a compound annual growth rate (CAGR) of 25.5% since 2015. The market is expected to grow from $4,390.3 million in 2020 to $15,482.3 million in 2025 at a rate of 28.7%. The market is then expected to grow at a CAGR of 17.3% from 2025 and reach $34,317.9 million in 2030.
Growth in the historic period in the cell and gene therapy market resulted from increase in investments in cell and gene therapies, growth in research and development, advances in cancer drug discovery, rise in public-private partnerships, strong economic growth in emerging markets, increased healthcare expenditure, and rising in pharmaceutical R&D expenditure. The market was restrained by inadequate reimbursements, challenges due to regulatory changes, low healthcare access, and limited number of treatment centers.
Going forward increasing prevalence of cancer and chronic diseases, rising geriatric population, rising geriatric population, rising focus on cell and gene therapy, and rise in healthcare expenditure will drive the growth in the cell and gene therapy market. Factors that could hinder the growth of the market in the future include high costs of therapy, stringent regulations, reimbursement challenges, and coronavirus pandemic.
The cell and gene therapy market is segmented by product into cell therapy, and gene therapy. The gene therapy market was the largest segment of the cell and gene therapy market segmented by product, accounting for 72.4% of the total in 2020. Going forward, the gene therapy segment is expected to be the fastest growing segment in the cell and gene therapy market segmented by product, at a CAGR of 30.8% during 2020-2025.
The cell and gene therapy market is also segmented by application into oncology, neurological disorders, and others. The oncology market was the largest segment of the cell and gene therapy market segmented by application, accounting for 64.6% of the total in 2020. Going forward, the neurological disorders segment is expected to be the fastest growing segment in the cell and gene therapy market segmented by application, at a CAGR of 30.7% during 2020-2025.
North America was the largest region in the global cell and gene therapy market, accounting for 49.8% of the total in 2020. It was followed by the Western Europe, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the cell and gene therapy market will be the Middle East and South America where growth will be at CAGRs of 60.5% and 59.9% respectively. These will be followed by Asia Pacific and Eastern Europe, where the markets are expected to register CAGRs of 49.4% and 38.9% respectively.
The coronavirus pandemic caused a global economic slowdown and impacted various industries across the world, including the cell and gene therapy market. Nationwide lockdowns and restrictions on activity to contain COVID-19 are disrupting supply chains and affecting manufacturing worldwide. The manufacturing, delivery of treatments, and commercial operations were heavily interrupted by the COVID-19 crisis. Cell and gene therapy companies around the globe reduced their manufacturing operations during the lockdowns imposed by governments. These companies are slowly resuming operations to full capacity as countries ease lockdown restrictions.
The global cell and gene therapy market is highly concentrated, with a small number of large players. The top ten competitors in the market made up to 97.46% share of the total market in 2019. Major players in the market include Biogen Inc., Novartis AG, Gilead Sciences, Ionis Pharmaceuticals, Inc., and Alnylam Pharmaceuticals, Inc.
The top opportunities in the cell and gene therapy market segmented by product will arise in the gene therapy segment, which will gain $8,977.0 million of global annual sales by 2025. The top opportunities in the cell and gene therapy market segmented by application will arise in the oncology segment, which will gain $6,730.2 million of global annual sales by 2025. The cell and gene therapy market size will gain the most in the USA at $3,360.9 million.
Market-trend-based strategies for the cell and gene therapy market include focusing on advanced therapies such as chimeric antigen receptor (CAR) T-cell therapy, concentrating on undertaking various research initiatives and attain funding, carrying out strategic collaborations to integrate advanced technologies, concentrating on developing gene/genome editing tools especially CRISPR, partnering or acquiring competitor companies, increasing the number of pipeline studies to develop cell and gene therapies, and investing in manufacturing facilities expansion.
Player-adopted strategies in the cell and gene therapy market include establishing business relationships or partnerships to develop and market innovative therapeutics, expanding product portfolio through acquiring similar companies, expanding cell and gene therapeutics business by getting marketing approvals in different geographies, expanding cell and gene therapy business through strategic collaborations, and developing new gene therapy on RNAi based therapeutics by collaborating with pharmaceutical and life sciences companies.
To take advantage of these opportunities, the publisher recommends the cell and gene therapy companies to consider investing in the development of advanced therapies such as chimeric antigen receptor (CAR) T-cell therapy to offer patients with better treatment options, work on strategic alliances collaborations to integrate advanced technologies in the manufacturing of cell and gene therapy, expanding activities to emerging markets to gain market share, offer skimmed pricing to attract the users, leverage e-commerce tools to reach targeted people, among other strategies.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Biogen Inc.
- Novartis AG
- Gilead Sciences
- Ionis Pharmaceuticals, Inc.
- Alnylam Pharmaceuticals, Inc.
- ArrowHead Pharmaceuticals Inc.
- Spark Therapeutics
- Bluebird Bio, Inc.
- RegenexBio
- Mesoblast Limited
- Biocon
- Cipla
- Stempeutics Research Pvt. Ltd.
- EdiGene, Inc.
- Immunochina
- Takara Bio
- Daiichi Sankyo Company
- Ultragenyx Pharmaceutical Inc
- Mitsubishi Tanabe Pharma
- Oxford Biomedica plc
- Santen Pharmaceutical Co.
- Therapeutic Innovation Australia
- Merck
- GenScript
- Cellular Biomedicine Group
- GE Healthcare
- inStem
- Lonza
- Nikon CeLL innovation Co. Ltd.
- Bristol-Myers Squibb
- Amgen
- Pfizer
- Albumedix Ltd
- Kite Pharma
- Catalent
- Oxford BioTherapeutics
- Freeline Therapeutics
- Avectas
- DiNAQOR AG
- Vivet Therapeutics
- Allergan
- Takeda Pharmaceutical
- PsiOxus Therapeutics
- Herantis Pharma Plc
- Biocad
- Celgene Corporation
- Johnson & Johnson
- F. Hoffmann-La Roche Ltd
- Eli Lilly and Company
- GlaxoSmithKline plc
- Biogen Brazil
- Takeda Pharmaceutical Company Limited
- Middle East Gene Therapy Company
- DEVA (Turkey)
- Biotchpharma (Turkey)
- Gene Vector Technologies (Israel)
- BrainStorm Cell Therapeutics (Israel)
- Pluristem (Israel)
- Sanofi
- Bayer East Africa Ltd.
- Adcock Ingram
Methodology
LOADING...
